Molecular structure of gefitinib
Find information on thousands of medical conditions and prescription drugs.

Iressa

Gefitinib is a new drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa®. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
Ibuprofen
Idarubicin
Idebenone
IFEX
Iloprost
Imatinib mesylate
Imdur
Imipenem
Imipramine
Imiquimod
Imitrex
Imodium
Indahexal
Indapamide
Inderal
Indocin
Indometacin
Infliximab
INH
Inosine
Intal
Interferon gamma
Intralipid
Invanz
Invirase
Iontocaine
Iotrolan
Ipratropium bromide
Iproniazid
Irbesartan
Iressa
Irinotecan
Isocarboxazid
Isoflurane
Isohexal
Isoleucine
Isomonit
Isoniazid
Isoprenaline
Isordil
Isosorbide
Isosorbide dinitrate
Isosorbide mononitrate
Isotretinoin
Itraconazole
Ivermectin
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Mechanism of action

Gefitinib is the first selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. The target protein (tyrosine kinase) is also sometimes referred to as Her1 or ErbB-1 depending on the literature source.

EGFR is overexpressed in the cells of certain types of human carcinomas - for example in lung and breast cancers. This leads to inappropriate activation of the apoptotic Ras signal transduction cascade, eventually leading to uncontrolled cell proliferation. Research on gefitinib-sensitive non-small cell lung cancers has shown that a mutation in the EGFR tyrosine kinase domain is responsible for activating anti-apoptotic pathways (Pao et al. 2004, Sordella et al. 2004). These mutations tend to confer increased sensitivity to tyrosine kinase inhibitors such as gefitinib and erlotinib. Of the types of non-small cell lung cancer histologies, adenocarcinoma is the type that most often harbors these mutations. These mutations are more commonly seen in Asians, women, and non-smokers (who also tend to more often have adenocarcinoma).

Gefitinib inhibits EGFR tyrosine kinase by binding to the adenosine triphosphate (ATP)-binding site of the enzyme. Thus the function of the EGFR tyrosine kinase in activating the Ras signal transduction cascade is inhibited, and malignant cells are inhibited.

Clinical uses

Gefitinib is currently only indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have previously received chemotherapy.

While gefitinib has yet to be proven to be effective in other cancers, there is certainly potential for its use in the treatment of other cancers where EGFR overexpression is involved.

In 2004, AstraZeneca informed the United States Food and Drug Administration (FDA) that a large randomized study failed to demonstrate a survival advantage for gefitinib in the treatment of non-small cell lung cancer (NSCLC). Whether progression-free survival is prolonged is not clear from this statement. AstraZeneca also withdrew their application to market gefitinib in Europe shortly after this announcement.

Erlotinib is another EGFR tyrosine kinase inhibitor that works in the same way as gefitinib. Given the lack of survival advantage for gefitinib and the positive results for erlotinib, erlotinib has replaced gefitinib in the United States.

Genzyme test

On September 26 2005, Genzyme Corp. announced that it would market a test to detect EGFR expression, designed to help predict which lung cancer patients may respond best to some therapies, including gefitinib and erlotinib. This method is used to identify ahead of time which patients may respond to medications in this drug class.

Read more at Wikipedia.org


[List your site here Free!]



Clinical trial of Iressa
In December 2004, the FDA learned from AstraZeneca Pharmaceuticals that a large clinical trial comparing Iressa (gefitinib) with an inactive substance ...
Myocarditis Temporally Related to the Use of Gefitinib (Iressa)
Gefitinib is a new drug that was approved by the US Food and Drug Administration in May 2003 for non-small cell cancer of the lung refractory to first- ...
Acneiform eruption induced by Iressa tablets used to treat non-small cell lung cancer
Abstract Many medications have been reported to induce acneiform eruptions. A relatively new chemotherapy drug, gefitinib (Iressa), approved by the ...
ZD1839 for recurrent or metastatic squamous cell carcinoma of the skin - Iressa® - Clinical Trial Review - Brief Article
This study is not yet open for patient recruitment. Sponsored by M.D. Anderson Cancer Center This is a Phase II trial to determine the effectiveness ...
AstraZeneca expects no discussion of Iressa at FDA's December meeting - Pharmacy Watch - Brief Article
LONDON -- AstraZeneca has dismissed reports that Iressa, its new lung cancer drug, might have to face a new U.S. regulatory probe. According to the drug manufacturer, a Food and Drug Administration
Schools of Pharmacology
Schools in Pharmacology is a new feature in that will appear periodically. It will explicate the dermatologic uses and side effects of new medications ...
Targeted attack: scientists declare war on a protein implicated in some stubborn forms of cancer
A rose may be a rose, no matter what you call it, but cancer does not follow the same rules. Although every cancer arises from an uncontrolled reproduction ...
Reflections on ASCO 2005
I have just returned from the 41st annual meeting of the American Society of Clinical Oncology (ASCO). Twenty-five thousand oncologists converged on ...

Home Contact Resources Exchange Links ebay